Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non-ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia [version 3; peer review: 2 approved, 1 approved with reservations]

Siprianus Ugroseno Yudho Bintoro, Ni Made Intan Dwijayanti, Dana Pramudya, Putu Niken Amrita, Pradana Zaky Romadhon, Tri Pudy Asmarawati, Arief Bachtiar, Usman Hadi

1Hematology – Medical Oncology Division, Department of Internal Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia
2Dr. Soetomo General Teaching Hospital, Surabaya, East Java, 60286, Indonesia
3Tropical and Infectious Diseases Division, Department of Internal Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia
4Department of Pulmonology and Respiratory Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia

Abstract

Background: This research aimed to examine and analyze risk factors for death, hematologic parameters and coagulation in COVID-19 patients at RSUD Dr. Soetomo Surabaya, one of the referral centers for probable COVID-19 patient cases in East Java.

Method: This was a retrospective analytical study by taking secondary data on patients with probable COVID-19 cases who were treated in hospital isolation rooms from May to September, 2020.

Result: Of 538 probable COVID-19 patients, 217 were tested positive, with an average age of 52.11±13.12 years, and there were 38 death cases. Hematologic parameters, such as white blood cell, neutrophil and lymphocyte counts, showed significantly different result in the deceased group. On the other hand, coagulation parameters, consisting of D-dimer, CRP, PT, and aPTT showed significantly similar value in the deceased group. Univariate analysis concluded that chronic kidney disease, diabetes mellitus, coronary heart disease, WBC, NLR, and PPT counts could predict the mortality, while multivariate analysis revealed that coronary heart disease was the
only significant independent predictor of mortality.

**Conclusion**: This research shows that hematologic and coagulation parameters increased in the majority of COVID-19 patients and the deceased group. While the number of neutrophils and WBC increases, the number of lymphocytes decreases significantly as the disease gets more severe. Coronary heart disease is an independent predictor of mortality.

**Keywords**
COVID-19, comorbid, hematology, coagulopathy, good health, and well-being

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus collection.

Corresponding authors: Siprianus Ugroseno Yudho Bintoro (ugroseno@fk.unair.ac.id), Usman Hadi (usman.hadi2@fk.unair.ac.id)

Author roles: **Bintoro SUY**: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Review & Editing; **Dwijayanti NMI**: Data Curation, Formal Analysis, Investigation, Project Administration, Software, Visualization, Writing – Original Draft Preparation; **Pramudya D**: Conceptualization, Formal Analysis, Project Administration, Resources, Visualization, Writing – Review & Editing; **Amrita PN**: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Validation, Visualization, Writing – Original Draft Preparation; **Romadhon PZ**: Investigation, Methodology, Project Administration, Software, Validation, Visualization, Writing – Original Draft Preparation; **Amarwati TP**: Conceptualization, Data Curation, Investigation, Methodology, Project Administration, Resources, Validation, Visualization, Writing – Original Draft Preparation; **Bachtiar A**: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation; **Hadi U**: Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Writing – Review & Editing

**Competing interests**: No competing interests were disclosed.

**Grant information**: Universitas Airlangga COVID-19 Grant 2020

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Copyright**: © 2021 Bintoro SUY et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article**: Bintoro SUY, Dwijayanti NMI, Pramudya D et al. Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non-ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia [version 3; peer review: 2 approved, 1 approved with reservations] F1000Research 2021, 10:791 https://doi.org/10.12688/f1000research.53803.3

First published: 11 Aug 2021, 10:791 https://doi.org/10.12688/f1000research.53803.1

Any reports and responses or comments on the article can be found at the end of the article.

Hospital Jakarta, South Jakarta, Indonesia
2. **Azlan Bin Husin** ID, Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia
Universiti Sains Malaysia, Kubang Kerian, Malaysia
3. **Simona Lattanzi** ID, Marche Polytechnic University, Ancona, Italy
Introduction

In December 2019, China reported a mysterious pneumonia case of unknown cause which had spread rapidly in Wuhan city. The World Health Organization (WHO) named this virus as the 2019 novel coronavirus (2019-nCoV),\(^1,2\) and the name was changed to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) by the Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses; the official name of the disease caused by the virus is COVID-19.\(^2,3\) COVID-19 is a major health concern at this time, especially for the elderly, due to the SARS-CoV-2 virus.\(^4,5\) This coronavirus has become the main pathogen, causing an outbreak of respiratory disease until it has been declared a pandemic, and spreading rapidly throughout the world, including Indonesia.\(^6\) COVID-19 has become a global problem today due to the high transmission and mortality rates.\(^7\)

As reported by Huang \textit{et al.}, patients with COVID-19 present primarily with fever, myalgia or fatigue, and dry cough.\(^7\) Although most patients are considered to have good prognoses, elderly patients, as well as those with underlying chronic conditions, may have worse outcomes. Severe patients may experience shortness of breath and hypoxemia within one week of disease onset, which can rapidly progress to acute respiratory distress syndrome (ARDS) or end-organ damage. Chronic cardiac and metabolic disease, the presence of acute inflammation as well as decreased organ (heart, kidney, liver, and hematalogy) function experienced by patients at the beginning of treatment, can increase the risk of death due to COVID-19 infection.\(^8,9\)

The need for COVID 19 patients to be hospitalized varies widely from country to country as it depends on the prevalence of community testing and admission criteria.\(^2,10\) However, it is estimated that one in 5–10 adult patients with disease severity and sufficient criteria to be hospitalized. Most of the patients with severe acute respiratory infections or severe acute respiratory syndrome were managed according to the case definition of WHO. The criteria for intensive care also vary from country to country. Old age, chronic disease, and male gender consistently associated with increased mortality.\(^10\)

Hematologic and coagulation parameters were important for predicting the severity of COVID-19. The occurrence of disseminated intravascular coagulation (DIC) is a common finding in COVID-19 patients.\(^11\) In addition, administering anticoagulant therapy to high-risk patients is effective in reducing mortality.\(^12,13\)

The first COVID-19 case in Indonesia was announced on March 2, 2020, four months after the first case in China.\(^14\) The first cases in Indonesia in March 2020 were two cases; and after that, two cases were noted on March 6th. COVID-19 cases continue to grow. In the beginning, there were hundreds of cases added; and until now, the number of cases has increased to thousands. On March 17, 2020, the government of East Java reported the first case of COVID-19, and as of July 31, 2020, there were 22,098 confirmed cases with a fairly high mortality rate of 7.6\%.\(^16\) Meanwhile, in July 2020, Surabaya reported 8,691 confirmed COVID-19 patients. The RSUD Dr. Soetomo (RSDS) Surabaya is one of the referral centres for probable COVID-19 patient cases in East Java. Based on the total cases, it is necessary to collect data, including clinical manifestations, risk factors, hematologic parameters, and coagulation which aggravate the condition of COVID-19 patients.\(^17\)

Several studies related to clinical manifestations and risk factors for COVID-19 patients have been reported previously; however, this research is based on relatively small sample size, and the risk factors that lead to poor clinical outcomes have not yet been well explained. In addition, probable and confirmed cases of COVID-19 at RSDS Surabaya had often presented with comorbidities, such as diabetes mellitus, high blood pressure, heart disease, hematological disorders, old age, chronic lung disease, stroke, and kidney disorders. This leads to discussion about which comorbid, hematologic parameters and coagulation factors may become predictive of COVID-19 mortality.
Methods
This was a retrospective analytical study, performed by taking secondary data on patients with probable COVID-19 cases who were treated at the special isolation room (non-intensive care) of the Department of Internal Medicine of the teaching hospital of RSUD Dr. Soetomo between May and September, 2020. The sample consisted of deceased and survived patients at the special isolation room (non-intensive care) of Internal Medicine of RSUD Dr. Soetomo, who had been hospitalized with probable COVID-19. Incusion criteria probable COVID-19 patients were aged more than 18 years old, showing clinical signs of pneumoniae. They are categorized into moderate pneumoniae with signs and symptoms as follows: fever, cough, dyspnea, tachypnea, and later grouped into the severe category with additional criteria, such as: RR > 30 times per minute, \( \text{O}_2 \text{ sat} < 93\% \text{ room air} \), also no mechanical support and ICU care needed. Patients with incomplete data were excluded.

According to hospitalized probable COVID-19 criteria, there were 538 probable cases. COVID-19 was diagnosed through sample taken from nasal swab and further RT PCR examination, 297 patients showed positive result, whereas the rest are negative. Of 297 patients, 80 had incomplete medical record, hence, 217 samples left eventually were included (see Figure 1).

Approval from the local ethics committee was obtained for this research; written informed consent was obtained from patients during hospitalization. From the hospital information database system, we retrieved patient characteristics such as age, gender, comorbidities, signs and symptoms, and laboratory results, including hemoglobin, white blood cell (WBC), neutrophil, lymphocyte, and platelet counts, D-dimer level, C-reactive protein (CRP), prothrombin time (PT), and activated partial thromboplastin time (aPTT).

---

**Figure 1. Patient COVID-19 data selection process.**
| Table 1. Laboratory and clinical overview of the deceased and survived patients. |
|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                              | Total (n = 217)               | Survival status               | p-value                       |
|                              | Not survive (n = 38)          | Survive (n = 179)             |                               |
| Age                          | 52.11 ± 13.12                 | 58.42 ± 12.78                 | 50.77 ± 12.83                 | <0.001*                      |
| Gender                       |                               |                               |                               |                               |
| Male                         | 116 (53.5)                    | 23 (60.5)                     | 93 (52.0)                     | 0.336                        |
| Female                       | 101 (46.5)                    | 15 (39.5)                     | 86 (48.0)                     |                               |
| Comorbid factors             | 129 (59.4)                    | 28 (73.7)                     | 101 (56.4)                    | 0.049                        |
| Diabetes (DM)                | 72 (33.2)                     | 18 (47.4)                     | 54 (30.2)                     | 0.041                        |
| Hypertension (HT)            | 66 (30.4)                     | 13 (34.2)                     | 53 (29.6)                     | 0.575                        |
| Coronary heart disease       | 4 (1.8)                       | 4 (10.5)                      | 0 (0)                         | <0.001*                      |
| Thyroid                      | 2 (0.9)                       | 0 (0)                         | 2 (1.1)                       | 0.680*                       |
| Obesity                      | 2 (0.9)                       | 0 (0)                         | 2 (1.1)                       | 0.680*                       |
| Malignancy                   | 10 (4.6)                      | 4 (10.5)                      | 6 (3.4)                       | 0.076*                       |
| CKD                          | 42 (19.4)                     | 27 (15.1)                     | 15 (39.5)                     | <0.001*                      |
| Regular HD                   | 11 (5.1)                      | 9 (5.0)                       | 2 (5.3)                       | 0.605*                       |
| Hepatitis B                  | 7 (3.2)                       | 4 (2.2)                       | 3 (7.9)                       | 0.105*                       |
| Chronic liver disease        | 5 (2.3)                       | 3 (1.7)                       | 2 (5.3)                       | 0.211*                       |
| Chronic lung disease         | 5 (2.3)                       | 0 (0)                         | 5 (2.8)                       | 0.378*                       |
| Symptoms                     |                               |                               |                               |                               |
| Short of breath              | 118 (54.4)                    | 25 (65.8)                     | 93 (52.0)                     | 0.120                        |
| Cough                        | 111 (51.2)                    | 19 (50.0)                     | 92 (52.4)                     | 0.876                        |
| Fever                        | 87 (40.1)                     | 19 (50.0)                     | 68 (38.0)                     | 0.170                        |
| Limp                         | 51 (23.5)                     | 11 (28.9)                     | 40 (22.3)                     | 0.383                        |
| Hoarseness                   | 0 (0)                         | 0 (0)                         | 0 (0)                         | -                            |
| Anosmia                      | 2 (0.9)                       | 0 (0)                         | 2 (1.1)                       | 0.680*                       |
| Nasal congestion             | 1 (0.5)                       | 0 (0)                         | 1 (0.6)                       | 0.825*                       |
| Watery eyes                  | 0 (0)                         | 0 (0)                         | 0 (0)                         | -                            |
| Muscle pain                  | 0 (0)                         | 0 (0)                         | 0 (0)                         | -                            |
| Diarrhea                     | 25 (11.5)                     | 4 (10.5)                      | 21 (11.7)                     | 0.833                        |
| Swallowing pain              | 9 (4.1)                       | 2 (5.3)                       | 7 (3.9)                       | 0.705                        |
| Headache                     | 5 (2.3)                       | 1 (2.6)                       | 4 (2.2)                       | 0.883                        |
| COVID-19 therapies           |                               |                               |                               |                               |
| Hydroxychloroquine           | 35 (16.1)                     | 2 (5.3)                       | 33 (18.4)                     | -                            |
| Oseltamivir                  | 14 (6.5)                      | 13 (7.3)                      | 1 (2.6)                       | -                            |
| Lopinavir                    | 38 (17.5)                     | 11 (28.9)                     | 27 (15.1)                     | -                            |
| Favipiravir (Avigan)         | 2 (0.9)                       | 0 (0)                         | 2 (1.1)                       | -                            |
| Laboratory parameters        |                               |                               |                               |                               |
| Hb (g/dL)                    | 12.27 ± 2.54                  | 11.75 ± 2.30                  | 12.38 ± 2.58                  | 0.075**                      |
| WBC (×10^9/L)                | 10.83 ± 9.64                  | 13.67 ± 11.83                 | 10.23 ± 9.03                  | 0.011**                      |
| Neutrophil abs (×10^9/L)     | 8.19 ± 7.39                   | 13.67 ± 11.13                 | 10.23 ± 6.16                  | 0.002**                      |
| Lymphocyte abs (×10^9/L)     | 1.46 ± 1.34                   | 1.39 ± 1.54                   | 1.48 ± 0.11                   | 0.074**                      |
| NLR                          | 8.53 ± 17.87                  | 15.57 ± 39.14                 | 7.04 ± 7.51                   | 0.003**                      |
Statistical analysis

Data analysis was performed using SPSS version 25 (Chicago, IL, USA; RRID:SCR_002865); JASP (RRID:SCR_015823) is an open access alternative. Patient characteristics (see Table 1) are presented as mean ± standard deviation or median, and interquartile ranges of 25th and 75th percentiles (IQR 1–3) or minimum and maximum, depending on the continuous distribution variable. Normality tests were performed and a comparison test for normal distribution data by an independent sample t-test and a Mann–Whitney test, otherwise. We used ANOVA to determine statistical differences among some groups with normally-distributed data. Contrarily, we carried out Kruskal Wallis analysis in groups with abnormally distributed ones. Comparison for the categorical variables were performed using Pearson’s and Fisher’s Exact Chi-squared tests. Survival analyses and Kaplan–Meier survival curves were performed for hemoglobin, white blood cell, neutrophil, lymphocyte, neutrophil–lymphocyte ratio, D-dimer, PT, aPTT, and CRP. The evaluation of independent predictors of mortality was performed by univariate and multivariate Cox regression analysis. Threshold mortality predictor from the laboratory parameter was also performed; the receiver–operating curve (ROC) analysis associated with the area under the curve (AUC) was used to find the optimal threshold value of the laboratory rate parameter to predict the progression of mortality in the study group. The AUC was interpreted as excellent if 0.9 < AUC < 1; good if 0.8 < AUC < 0.9; moderate if 0.7 < AUC < 0.8; poor if 0.6 < AUC < 0.7; and fail if 0.5 < AUC < 0.6.

Results

538 patients with probable COVID-19 were included during the study period in which. 288 (53.5%) were males, with the mean ± SD age of 51.69 ± 13.67 years. More than half of the patients (63.7%) had elemental diseases, including diabetes mellitus (34%), hypertension (32.5%), and CKD (22.7%). All the patients with probable COVID-19 experienced symptoms on arrival, including complaints of shortness of breath (48.7%), cough (40%), fever (32%), and limp (24%). Some patients also complained of diarrhea and headache but it was only at 10.2% and 3.2%, respectively.

Demographic and clinical overview and laboratory results of the COVID-19 patient study group

In total, we included 217 hospitalized patients with a diagnosis of COVID-19; they were 116 male patients and the male-to-female ratio was 1.14. The average age of this retrospective research was 52.11 ± 13.12 years. The most common chronic disease (comorbid) among patients was diabetes (33.2%). The clinical and demographic characteristics and laboratory results are shown in Table 1.

Comparison of laboratory parameters in deceased and survived patients

From 217 patients, 38 patients (17.5%) died. They were significantly older than those who survived (mean 58.42 ± 12.78 years versus 50.77 ± 12.83 years, respectively; p < 0.001). The majority of the deceased patients had at least one comorbidity (73%), while 56.4% of the patients who survived had comorbid factors (p = 0.049). The common comorbidities that were significantly different were diabetes mellitus, hypertension, and coronary heart disease in the group of deceased patients than in those who survived. We stratified laboratory markers that we divided based on normal lab values. In deceased patients, the white blood cell, neutrophil, and lymphocyte counts showed significant difference between groups. Otherwise, D-dimer, PT, aPTT, and CRP did not show any differences (see Table 2).

Inflammatory markers (leukocyte, C-reactive protein, neutrophil count and NLR) were significantly higher in the deceased group than in the group who survived. While the normal leukocyte and neutrophil counts were significantly more common in the patients who survived, and lymphopenia was significantly more common in deceased patients (p = 0.048). Meanwhile, the frequency of thrombocytopenia and the increase in D-dimer were comparable between two groups. Neutropenia, leukopenia, lymphopenia, higher CRP, NLR, and PT correlated with COVID-19 patients’ mortality.

### Table 1. Continued

| Total (n = 217) | Survival status |
|----------------|----------------|
|                | Not survive (n = 38) | Survive (n = 179) |
| PLT count (×10^9/L) | 298.87 ± 174.02 | 315.28 ± 253.73 | 295.39 ± 152.63 | 0.953** |
| aPTT (second)     | 28.82 ± 9.14     | 31.37 ± 17.40   | 28.28 ± 6.07    | 0.635** |
| PPT (second)      | 12.58 ± 6.81     | 15.06 ± 14.27   | 12.06 ± 3.52    | 0.103** |
| D-Dimer (ng/dL)   | 3593.15 ± 5380.45| 6767.55 ± 8655.18| 2919.26 ± 4117.03| <0.001** |
| CRP (mg/dL)       | 12.95 ± 45.54    | 17.80 ± 11.55   | 11.92 ± 49.83   | <0.001** |

*Fischer Exact test.
**Mann-Whitney test.
The ROC analysis using sensitivity and specificity based on mortality predictor revealed that there was an optimal cut-off value for several laboratory parameters including WBC count, neutrophil count, CRP level, D-dimer, and NLR count. The largest AUC value was CRP with a cut-off value of \( \geq 1.85 \) (sensitivity = 94.7% and specificity = 72.1%). NLR, WBC count, neutrophil count, D-dimer, and CRP as mortality predictors showed good results (see Table 3).

**Survival analysis**

The Kaplan–Meier graph showed that leukocyte count, neutrophil count, NLR, PT, and CRP associated with patients mortality, that they can be used to predict it (p < 0.05, respectively) (see Figure 2). Moreover, lower survival rate was shown from leukopenia, leukocytosis, neutrophilia, high NLR, high CRP, and prolonged PT (p = 0.015; p = 0.018, p = 0.003, p = 0.035, and p = 0.03, respectively).

| **Table 2. Comparison of laboratory results in deceased and survived patients.** |
|----------------------------------------|---------|----------------|---------------|----------------|
| Hemoglobin (g/dL) (%)                  | Total   | Survival status | p-value       |
|                                        | (n = 217) | Not survive (n = 38) | Survive (n = 179) |                |
| <12                                    | 78 (35.9) | 20 (52.6) | 58 (52.4) | 0.052* |
| 12-16                                  | 136 (62.7) | 18 (47.4) | 118 (65.9) |                |
| >16                                    | 3 (1.4) | 0 (0) | 3 (1.7) |                |
| WBC (leucocyte) \( (\times 10^9) \) (%) | <4.0 | 13 (6.0) | 2 (5.3) | 11 (6.1) | 0.028 |
|                                        | 4.0-10.0 | 125 (57.6) | 15 (39.5) | 110 (61.5) |                |
|                                        | >10.0 | 79 (36.4) | 21 (55.3) | 28 (32.4) |                |
| Neutrophil count \( (\times 10^9) \) (%) | <2.0 | 9 (4.1) | 2 (5.3) | 7 (3.9) | 0.006 |
|                                        | 2.0-7.0 | 119 (54.8) | 12 (31.6) | 107 (59.8) |                |
|                                        | >7.0 | 89 (41.0) | 24 (63.2) | 65 (36.3) |                |
| Lymphocyte count \( (\times 10^9) \) (%) | <0.8 | 47 (21.7) | 12 (31.6) | 35 (19.6) | 0.048* |
|                                        | 0.8-4.0 | 166 (76.5) | 24 (63.2) | 142 (79.3) |                |
|                                        | >4.0 | 4 (1.8) | 2 (5.3) | 2 (1.1) |                |
| Platelet count \( (\times 10^9) \) (%) | <150 | 27 (12.4) | 3 (7.9) | 24 (13.4) | 0.588* |
|                                        | 150-450 | 164 (75.6) | 31 (81.6) | 133 (74.3) |                |
|                                        | >450 | 26 (12.0) | 4 (10.5) | 22 (12.3) |                |
| Above-normal result percentages         | C-reactive protein (%) | 192 (88.5) | 37 (97.4) | 155 (86.6) | 0.042 |
|                                        | D-dimer (%) | 203 (93.5) | 36 (94.7) | 167 (93.3) | 0.543 |
|                                        | Prothrombin time (%) | 12 (5.5) | 5 (13.2) | 7 (3.9) | 0.039 |
|                                        | aPTT (%) | 7 (3.2) | 2 (5.3) | 5 (2.8) | 0.354 |
|                                        | NLR | 154 (71) | 33 (86.8) | 121 (67.6) | 0.018 |

*Kruskal-Wallis test.

Neutrophil-lymphocyte ratio (NLR), Lactate dehydrogenase (LDH), International normalized ratio (INR), Activated partial thromboplastin time (aPTT). Normal laboratory reference values: CRP: 0–5mg /L, D-dimer: 0–500 ng/mL, PT: 11–16 seconds, aPTT: 25–40 seconds.

The ROC analysis using sensitivity and specificity based on mortality predictor revealed that there was an optimal cut-off value for several laboratory parameters including WBC count, neutrophil count, CRP level, D-dimer, and NLR count. The largest AUC value was CRP with a cut-off value of \( \geq 1.85 \) (sensitivity = 94.7% and specificity = 72.1%). NLR, WBC count, neutrophil count, D-dimer, and CRP as mortality predictors showed good results (see Table 3).

**Determining independent predictors of mortality**

We included age (as a categorical variable of under and over 65 years old), presence of chronic kidney disease, diabetes mellitus, coronary heart disease, and indicators, such as WBC count, NLR, CRP, PT, aPTT, and D-dimer for determining the predictors of mortality. In the univariate analysis, the independent predictors of mortality were shown from presence of chronic kidney disease, diabetes mellitus, coronary heart disease, WBC count, NLR, and PPT. However, based on the
Cox multivariate regression analysis, only coronary heart disease significantly became the independent predictor of mortality (see Table 4).

Discussion

Significant differences were found in the demographic and clinical variables, and hematologic and coagulation parameters between the deceased and surviving COVID-19 patients. We included age in the risk factor for COVID-19 mortality, whereas the age had a p-value <0.05. The age factor appeared to be crucial for the outcome of COVID-19. The average age of the deceased patients was 58 years old and was significantly older than the surviving patients. This was in accordance with previous studies that older age has been reported as an important independent predictor of mortality in SARS-Cov2.15,16 Increasing age also increased the percentage of COVID-19 mortality, the age-dependent defects in T-cell and B-cell function could lead to a deficiency in control of viral replication and more prolonged pro-inflammatory responses, potentially leading to poor outcome.17

Gender was proven to be a risk factor for mortality in COVID-19 patients, which was higher for men than for women. This is thought to be due to differences in the immunological systems of men and women, differences in lifestyle, and the prevalence of smoking.18 In this research, although statistically insignificant, the percentage of the number of male COVID-19 patients was higher, both overall and in the group of deceased patients. The higher mortality rates were associated with the higher chronic comorbidities in men, e.g., diabetes mellitus, kidney disease, hypertension, heart disease, lung disease, and smoking.19

The comorbid factors of diabetes mellitus, heart disease, and chronic kidney disease in COVID-19 patients could be the risk factors of death in this research, with a p-value of <0.05. Previous studies have described that the presence of common comorbidities increase COVID-19 patients risk. This result was similar to the meta-analysis study conducted by Mantovani et al., who stated that the prevalence of diabetic patients hospitalized due to COVID-19 was 14.34%, and 11.06% in patients in Asian countries. Meanwhile, the prevalence in non-Asian countries was higher, which was 23.34%. The risk of worsening the condition to require treatment in hospital was greater in COVID-19 patients with pre-existing diabetes.20 However, the specific comorbidity by which can lead to disease progression remain unknown in COVID-19 patients.21

For the hematologic parameters in this research, the leukocyte, neutrophil counts, lymphocyte count, and NLR demonstrated significantly different result between two groups. This research results were consistent with several previously published studies.22,23 On the other hand, the platelet count in this research was comparable between the groups of deceased and surviving patients. This was in contrast with the results of a meta-analysis that concluded by Lippi et al., who showed that thrombocytopenia was associated with increasing severity risk and mortality of COVID-19.24 Differences in pathophysiological mechanisms in each patient may lead to insignificant findings in this research. Many researchers have studied the changes in peripheral blood cell counts in COVID-19, and the results were that in infected patients, the white blood cell and neutrophil count increased, otherwise, the lymphocyte and platelet counts decreased.25 In the other cases, coagulation abnormalities (prolonged PT and aPTT) and intravascular coagulopathy (DIC) were so correlated with low platelet count.26

| Table 3. Sensitivity and specificity of laboratory parameters. |
|-------------------------------------------------------------|
| **AUC** | **Sensitivity** | **Specificity** | **Cut-off** | **95% CI** | **p-value** |
|----------|----------------|----------------|-------------|------------|-------------|
| Hemoglobin (g/dL) | 0.408 | 0.782 | 0.658 | >10.85 | 0.311-0.505 | 0.075 |
| WBC (x 10^9) | 0.631 | 0.620 | 0.737 | ≥7090 | 0.534-0.728 | **0.011** |
| Neutrophil count (x 10^9) | 0.663 | 0.961 | 0.947 | ≥2080 | 0.570-0.756 | **0.002** |
| Lymphocyte count (x 10^9) | 0.408 | 0.765 | 0.632 | ≥859 | 0.306-0.509 | 0.074 |
| Platelet count (x 10^9) | 0.497 | 0.687 | 0.684 | ≥208000 | 0.401-0.593 | 0.953 |
| C-reactive protein | 0.773 | 0.947 | 0.721 | ≥1.85 | 0.693-0.852 | **<0.001** |
| D-dimer | 0.679 | 0.939 | 0.974 | ≥410 | 0.586-0.772 | **<0.001** |
| Prothrombin time | 0.584 | 0.877 | 0.895 | ≥9.95 | 0.476-0.692 | 0.103 |
| aPTT | 0.525 | 0.385 | 0.421 | ≥29 | 0.428-0.621 | 0.635 |
| NLR | 0.652 | 0.592 | 0.789 | ≥3.88 | 0.563-0.743 | **0.003** |
Figure 2. Kaplan-Meier survival curves white blood cell count (WBC), neutrophil count, lymphocyte count, neutrophil-lymphocyte ratio (NLR), platelet count, aPTT, prothrombin time, D-Dimer, and CRP.
Figure 2. (continued)
The extreme inflammation is usually evidenced by elevated serum of CRP, IL-6, and PCT which indicate the increasing of COVID-19 severity.\textsuperscript{27} High levels of CRP and procalcitonin in COVID-19 patients also associated with the progression of ARDS, myocardial injury, and death.\textsuperscript{27,28} The presence of secondary bacterial infection would be an additional explanation of this increase in inflammatory biomarkers. This is consistent with this research which showed that serum CRP levels were significantly higher in the cohort of deceased COVID-19 patients. Therefore, we believe that the use of CRP as a biomarker in monitoring the progress and severity of COVID-19 patients will be considerably beneficial.

D Dimer in our study were measured using ELFA (enzyme linked fluorescent assay) method and cut off point 0.410 µg/ml. Several literatures showed different cut off point for D Dimer. Poudel, 2021 with 182 subject research showed D Dimer level 1.5 µg/ml were an optimal cut off point to predict mortality.\textsuperscript{29} While Zhang, 2020 with 343 subjects shows D Dimer level 2 µg/ml were an optimal cut off point.\textsuperscript{30} Guan, 2020 in China with 1099 subjects showed that non-survivors had a significantly higher D-dimer (median: 2.12 $\mu$g/ml) than that of survivors (median: 0.61 $\mu$g/ml).\textsuperscript{31} This result could be due to differences in measurement methods as disclosed by Favaloro et al. who stated several things regarding the measurement and reporting quality of D-dimers such as the measurement method, cut-off value, or D-dimer unit [D-dimer unit (DDU)] can lead to different research results.\textsuperscript{32} Other factors in our study that can affect D dimer level were our patients were older with median age 52, comorbidities such as cardiovascular disease and liver disease. Liver disease can affects D Dimer elimination from blood. In this study D dimer level was also measured on admission, very early in disease course. The half-life of D-dimer was approximately 8 hours therefore, serial measurement of D-dimer will shows more information.

PT and aPTT prolongation may occur during severe COVID-19, yet the increase is not as high as what has been observed in bacterial sepsis and DIC. A meta-analysis conducted by Henry et al.\textsuperscript{25} found that patients with severe and fatal COVID-19 had significantly higher coagulation parameters (especially PT) than patients with the non-severe ones. This is consistent with this research where there was an increase in aPTT, albeit insignificant, and a significant increase in PT with p < 0.05 in the group of deceased patients. Although it is not completely clear how SARS-CoV-2 activates the coagulation cascade, it may be associated as a by-product of cytokine storms.\textsuperscript{33} Researchers detected a significant extension in coagulation tests in this research, consistent with previously published studies.\textsuperscript{25,34} The mechanism of these changes is still not fully explained, however, the extension of the coagulation test, \textit{i.e.,} increased PT and aPTT, can be considered as a marker of disease severity and activation of the coagulation cascade and virus-induced cytokine storm.\textsuperscript{13,35}

For as much as this research was a retrospective study, several parameters were not completely listed such as level of ferritin, fibrinogen, procalcitonin, and IL-6, that we considered this as one of our research limitations. Since the development of complications that have occurred in patients are not thoroughly documented, we could not confidently say that inflammatory and coagulation factor disorders are more frequent in severe COVID-19. The only outcome measure of this research was patient mortality in hospital. Although researchers evaluated platelet count and D-dimers, the

| Table 4. Multivariate with Cox regression analysis. |
|-----------------------------------------------|
|                                               |
|                  | Crude HR (95% CI) | Crude p-value | Adjusted HR (95% CI) | Adjusted p-value |
| Age >65 years old: exists or not               | 2.05 (0.99-4.23)  | 0.051         |                   |                 |
| Hypertension: exists or not                    | 1.16 (0.59-2.28)  | 0.647         |                   |                 |
| CKD: exists or not                             | 2.76 (1.44-5.29)  | 0.002         | 1.64 (0.78-3.41)  | 0.185           |
| Diabetes mellitus: exists or not               | 1.95 (1.03-3.71)  | 0.039         | 1.69 (0.84-3.39)  | 0.136           |
| Coronary heart disease: exists or not          | 9.24 (3.20-26.67) | <0.001        | 11.56 (3.24-41.26) | <0.001          |
| Platelet count: high or normal                 | 0.971 (0.34-2.74) | 0.956         |                   |                 |
| WBC count: high or normal                      | 2.47 (1.29-4.69)  | 0.006         | 1.58 (0.76-3.29)  | 0.216           |
| NLR: high or normal                            | 2.91 (1.13-7.47)  | 0.026         | 1.81 (0.66-4.98)  | 0.247           |
| C-reactive protein: high or normal             | 6.31 (0.86-46.30) | 0.070         |                   |                 |
| Prothrombin time: high or normal               | 2.68 (1.04-6.91)  | 0.040         | 1.91 (0.67-5.39)  | 0.222           |
| aPTT: high or normal                           | 2.24 (0.53-9.34)  | 0.268         |                   |                 |
| D-Dimer                                        | 1.42 (0.34-5.93)  | 0.630         |                   |                 |

The extreme inflammation is usually evidenced by elevated serum of CRP, IL-6, and PCT which indicate the increasing of COVID-19 severity.\textsuperscript{27} High levels of CRP and procalcitonin in COVID-19 patients also associated with the progression of ARDS, myocardial injury, and death.\textsuperscript{27,28} The presence of secondary bacterial infection would be an additional explanation of this increase in inflammatory biomarkers. This is consistent with this research which showed that serum CRP levels were significantly higher in the cohort of deceased COVID-19 patients. Therefore, we believe that the use of CRP as a biomarker in monitoring the progress and severity of COVID-19 patients will be considerably beneficial.
International Society on Thrombosis and Hemostasis (ISTH) scores of the patients were not calculated, thus patients who had mild-to-moderate coagulation disorders could not be distinguished from who had a DIC.

**Conclusion**

This research indicates that hematologic and coagulation parameters are increased in the majority of COVID-19 patients and the group of deceased patients. As the neutrophil count and WBC increase, the lymphocyte count declines significantly along with the increase in disease severity. Coronary heart disease is an independent predictor of mortality.

**Data availability**

Underlying data

Figshare: Underlying data for 'Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non-ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia'. https://doi.org/10.6084/m9.figshare.14673060.

The project contains the following underlying data:

- Hema_Coagul_parameter_COVID.xlsx (main data).
- readme.docx (index).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

**Consent**

Written informed consent was received from the patients during hospitalization.

**Acknowledgments**

Researchers greatly appreciate to Dr. Joni Wahyuhadi, dr., Sp.BS(K) as the director in Dr. Soetomo General Teaching Hospital who has facilitated us in conducting research and Dr. Soebagjo Adi Soelistijo, dr.,Sp.PD.,KEMD.,FINASIM for giving us the opportunity to get research grant and facilitating us to collect data in internal medicine wards and intellectual discussion leading to research idea.

**Ethical statement**

The research ethics committee Dr. Soetomo General Academic Hospital (No: 0039/KEPK/VIII/2020).

**References**

1. Zhou P, Lou YX, Wang XG, et al.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-3.
   PubMed Abstract | Publisher Full Text | Free Full Text
2. WHO: Clinical management of COVID-19, interim guidance 27 May 2020. 2020. 55 p.
   Reference Source
3. (WHO): WHO: Coronavirus disease COVID-19 - Situation Report – 142 Data. Saf Risk Pharmacother. 2020; 1: B: 3-8.
   Reference Source
4. Gormbelyna AE, Baker SC, Baric RS, et al.: Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the Coronavirus Study Group. bioRxiv. 2020.
   Publisher Full Text
5. Ji W, Wang W, Zhao X, et al.: Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020 Apr 19; 92(4): 433–40.
   PubMed Abstract | Publisher Full Text | Free Full Text
6. Khižňová Azárová M, Setiatí S: COVID-19 and Indonesia. Acta Med Indones. 2020; 52(1): 84-9.
   Reference Source
7. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb; 395(10223): 497-506.
   PubMed Abstract | Publisher Full Text | Free Full Text
8. Yang W, Cao Q, Qin L, et al.: Clinical Characteristics and Imaging Manifestations of the 2019 novel coronavirus disease (COVID-19): A Multi-center study in Wenzhou City, Zhejiang, China. J Infect. 2020; 80(February): 388-93.
   PubMed Abstract | Publisher Full Text | Free Full Text
9. Yang W, Yan F: Patients with RT-PCR-confirmed COVID-19 and Normal Chest CT. Radiology. 2020 May; 295(2): E3-E3.
   PubMed Abstract | Publisher Full Text | Free Full Text
10. Docherty AB, Harrison EM, Green CA, et al.: Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2020; (April): 1-21.
    Publisher Full Text
11. Tang N, Li D, Wang X, et al.: Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thorac Haematol. 2020; 18(4): 844-7.
    PubMed Abstract | Publisher Full Text | Free Full Text
12. Rico-Mesa J, Rosas D, Ahmadian-Tehrani A, et al.: The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Curr Cardioi Rep. 2020; 22(7): 1-6.
    PubMed Abstract | Publisher Full Text | Free Full Text
13. Shang W, Dong J, Ren Y, et al.: The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020; 92(10): 2188–92.
    PubMed Abstract | Publisher Full Text | Free Full Text
14. Isbaniah F: Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Germas. 2020: 0-115.
    Reference Source
15. Chan JFW, Yuan S, Kok KH, et al.: A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: a Study of a Family Cluster. Lancet. 2020;
23. Tatum D, Taghavi S, Houghton A, et al.: A Novel Coronavirus from Patients with Pneumonia in China. 2019. N Engl J Med. 2020 Feb 20; 382(8): 727–33.
PubMed Abstract | Publisher Full Text | Free Full Text

16. Zhu N, Zhang D, Wang W, et al.: Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study. Lancet. 2020; 395(10229): 1054–62.
PubMed Abstract | Publisher Full Text | Free Full Text

17. Zhou F, Yu T, Du R, et al.: Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J Clin Invest. 2020; 130(5): 2620–9.
PubMed Abstract | Publisher Full Text | Free Full Text

18. Wenham C, Smith J, Morgan R: Does comorbidity increase the risk of mortality in hospitalized patients with COVID-19? J Clin Invest. 2020; 130(5): 2620–9.
PubMed Abstract | Publisher Full Text | Free Full Text

19. Lancet T: The gendered dimensions of COVID-19. Lancet. 2020; 395(10231): 1168.
PubMed Abstract | Publisher Full Text | Free Full Text

20. Mantovani A, Byrne CD, Zheng M: Diabetes as a Risk Factor for Greater COVID-19 Severity and In-Hospital Death: A Meta-Analysis of Observational Studies. Nutr Metab Cardiovasc Dis. 2020; 30(January): 1236–48.
PubMed Abstract | Publisher Full Text | Free Full Text

21. Wang B, Li R, Lu Z, et al.: Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients. Shock. 2020; 54(3): 652–8.
PubMed Abstract | Publisher Full Text | Free Full Text

22. Liu Y, Du X, Chen J, et al.: Neutrophil-to-Lymphocyte Ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020; 81(1): 1–12.
PubMed Abstract | Publisher Full Text | Free Full Text

23. Tatum D, Taghavi S, Houghton A, et al.: Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients. Shock. 2020; 54(3): 652–8.
PubMed Abstract | Publisher Full Text | Free Full Text

24. Lippi G, Plebani M, Michael B: Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020; 506(January): 145–8.
PubMed Abstract | Publisher Full Text | Free Full Text

25. Henry BM, de Oliveira MHS, Benoît S, et al.: Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7): 1021–8.
PubMed Abstract | Publisher Full Text

26. Bao C, Tao X, Cui W, et al.: SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol. 2020; 9:16–1.
PubMed Abstract | Publisher Full Text | Free Full Text

27. Chen G, Wu D, Guo W, et al.: Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J Clin Invest. 2020; 130(5): 2620–9.
PubMed Abstract | Publisher Full Text | Free Full Text

28. Huang I, Pranata R, Lim MA, et al.: C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020 Jan 21; 14(6): 17534662093717.
PubMed Abstract | Publisher Full Text | Free Full Text

29. Poudeur A, Poudeur V, Adhikari A, et al.: D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021; 16(8): e0256744.
PubMed Full Text
Simona Lattanzi
Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy

The Authors did not address any of the issues raised in my previous report. The issues should be considered in revising the manuscript.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Azlan Bin Husin
1 Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia
2 School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia

Congratulations, all comments has been addressed well.
Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical hematology, benign hematology, malignant hematology, autologous hematopoietic stem cell transplant

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

Simona Lattanzi

Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy

This was a retrospective study aiming to evaluate the clinical and laboratory predictors of mortality in COVID-19 patients.

The study is interesting and provides useful information in clinical practice. There are, however, some issues that need to be further addressed.

Were levels of interleukins available? Could you explore any correlations with the other identified predictors?

There is increasing evidence that easily obtainable laboratory biomarkers can have a predictive role and be used for diagnosis and outcome prediction in a variety of medical conditions not limited to infectious pathologies, but also including major cardiac events (ref 1), cerebral hemorrhage (ref 2), ischemic stroke (ref 3; ref 4), and cancers (ref 5; ref 6). In light of the suggested evidence, please put the study findings into the current research context by adding a brief synthesis about the meaning and wide potentialities of easy to obtain and inexpensive serum biomarkers in everyday clinical practice.

References
1. Tamhane UU, Aneja S, Montgomery D, Rogers EK, et al.: Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008; 102 (6): 653-7 PubMed Abstract | Publisher Full Text
2. Lattanzi S, Cagnetti C, Rinaldi C, Angelocola S, et al.: Neutrophil-to-lymphocyte ratio improves outcome prediction of acute intracerebral hemorrhage. Journal of the Neurological Sciences. 2018; 387: 98-102 Publisher Full Text
3. Lattanzi S, Norata D, Divani AA, Di Napoli M, et al.: Systemic Inflammatory Response Index and Futile Recanalization in Patients with Ischemic Stroke Undergoing Endovascular Treatment. *Brain Sci.* 2021; 11(9). PubMed Abstract | Publisher Full Text

4. Świtońska M, Piekuś-Słomka N, Słomka A, Sokal P, et al.: Neutrophil-to-Lymphocyte Ratio and Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients Undergoing Revascularization. *Brain Sci.* 2020; 10(11). PubMed Abstract | Publisher Full Text

5. Howard R, Kanetsky P, Egan K: Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Scientific Reports.* 2019; 9(1). Publisher Full Text

6. Xie Q, Chen P, Hu W, Sun P, et al.: The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. *Journal of Translational Medicine.* 2018; 16(1). Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Neurology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 28 September 2021

https://doi.org/10.5256/f1000research.77444.r94904

© 2021 Rachman A et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Andhika Rachman
Department of Hematology and Medical Oncology, University of Indonesia, Jakarta, Indonesia
Bayu Rumondor
Kebayoran Baru General Hospital Jakarta, South Jakarta, Indonesia

There are no further comments. Thank you for the revision

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology, Cancer thrombosis, and Platelets

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 31 August 2021
https://doi.org/10.5256/f1000research.57221.r91683

© 2021 Husin A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Azlan Bin Husin
1 Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia
2 School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia

1. Policy or criteria for hospital admission is important information to be included or at least discussed

2. Inclusion of patients who were not having COVID19 is not relevant in this research, unless author want to compare between positive vs negative group

3. This study used secondary data retrieved in respective manner; hence the documentation for informed consent from each patients is irrelevant

4. Operational definition for relevant co-morbidities were not available eg: thyroid disease (hypothyroid or hyperthyroid) or coronary artery disease (was it based on coronary angiogram or ECG or echocardiogram only or self declaration), etc.

5. Mortality should be defined - whether it is overall or specific of any term

6. Should look into more meaningful key points to compare between this study results with other published reports.

   Eg: a) Regarding age: comparing mean age is better. While discussing on this point it is important to consider relevant differences in study population (eg: hospital admission criteria that may include age, presence of co-morbidity etc)

7. Some statements were too strong and not supported by cited reference e.g. paragraph 2 (regarding gender issues), paragraph 3 (on elderly and diabetes), and paragraph 4 (about pathophysiologic mechanism) of the discussion.

8. Discussion on D-dimer should be supported by comparing the method and cut off point used in this study versus with other published data. Should also look into possible confounding factors like superimposed infection or may be smaller number of patients

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
No

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
No

Are the conclusions drawn adequately supported by the results?
No

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** clinical hematology, benign hematology, malignant hematology, autologous hematopoietic stem cell transplant

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 31 Aug 2021

**Siprianus Ugroseno Yudho Bintoro**, Airlangga University, Surabaya, Indonesia

Dear reviewer,

Thank you for reviewing and sending the feedback. We are going to revise it real soon.

warm regards,

Research Team

**Competing Interests:** No competing interests were disclosed.

Author Response 18 Nov 2021

**Siprianus Ugroseno Yudho Bintoro**, Airlangga University, Surabaya, Indonesia

**Comment 1:**
Policy or criteria for hospital admission were compliant with hospital policy which are:
confirmed or suspected Covid-19, who are symptomatic plus any of following criteria.

1. Age > 65 years.
2. Clinical or radiologic evidence of pneumonia.
3. $O_2$ saturation $\text{Spo}_2 < 99\%$.
4. Acute respiratory distress syndrome.
5. COPD
6. CKD
7. Acute compilation of diabetes mellitus.
8. Obesity (BMI $\geq 40$).
9. Acute malignancy.
10. Other to illness by physician description.

We included inclusion and exclusion criteria in Methods paragraph 2 in the revised version.

**Comment 2:**
We appreciate your very helpful comments. We included the probable patients to show the magnitude of Covid-19 probable cases in our referral hospital.

**Comment 3:**
We appreciate your very helpful comment. However we already have the informed consent to use patient's secondary administrative during their time of admission.

**Comment 4:**
Thank you for your very helpful comment. Comorbidities were recorded at admission by attending clinical staff (board certified interns), either by history taking, records from previous visits in our hospital, or previous laboratory result assessment, or patient reporting. We added it in the manuscript: Methods paragraph 2

**Comment 5:**
Thank you for your suggestion. In patients with confirmed Covid-19 we use the definition of mortality based on the WHO definition: death resulting from a clinically compatible illness in a probable or confirmed Covid-19 case, unless there is a clear alternative cause of death that cannot be related to Covid-19 (e.g trauma). There should be no period of complete recovery between the illness and death.

**Comment 6:**
We appreciate your comment, we revised our manuscript in Discussion, paragraphs 1 to 4.

Significant differences were found in the demographic and clinical variables, and hematologic and coagulation parameters between the deceased and surviving COVID-19 patients. We included age in the risk factor for COVID-19 mortality, whereas the age had a p-value <0.05. The age factor appeared to be crucial for the outcome of COVID-19. The average age of the deceased patients was 58 years old and was significantly older than the surviving patients. This was in accordance with previous studies that older age has been reported as an important independent predictor of mortality in SARS-Cov2. Increasing age also increased the percentage of COVID-19 mortality, the age-dependent defects in T-cell and B-cell function could lead to a deficiency in control of viral replication and more prolonged proinflammatory responses, potentially leading to poor outcome.

**Comment 7:**
Gender was suspected to be a risk factor for mortality in COVID-19 patients, which was higher for men than for women. This is thought to be due to differences in the immunological systems of men and women, differences in lifestyle, and the prevalence of smoking. In this research, although statistically insignificant, the percentage of the number of male COVID-19 patients was higher, both overall and in the group of deceased patients. The higher mortality rates were associated with the higher chronic comorbidities in men, e.g., diabetes mellitus, kidney disease, hypertension, heart disease, lung disease, and smoking.

The comorbidity factors of diabetes mellitus, heart disease, and chronic kidney disease in COVID-19 patients could be the risk factors of death in this research, with a p-value of <0.05. Previous studies have described that the presence of common comorbidities increase...
COVID-19 patients risk. This result was similar to the meta-analysis study conducted by Mantovani et al., who stated that the prevalence of diabetic patients hospitalized due to COVID-19 was 14.34%, and 11.06% in patients in Asian countries. Meanwhile, the prevalence in non-Asian countries was higher, which was 23.34%. The risk of worsening the condition to require treatment in hospital was greater in COVID-19 patients with pre-existing diabetes. However, the specific comorbidity by which can lead to disease progression remains unknown in COVID-19 patients.

For the hematologic parameters in this research, the leukocyte, neutrophil counts, lymphocyte count, and NLR demonstrated significantly different result between two groups. These research results were consistent with several previously published studies. On the other hand, the platelet count in this research was comparable between the groups of deceased and surviving patients. This was in contrast with the results of a meta-analysis that concluded by Lippi et al., who showed that thrombocytopenia was associated with increasing severity risk and mortality of COVID-19. Differences in pathophysiological mechanisms in each patient may lead to insignificant findings in this research. Many researchers have studied the changes in peripheral blood cell counts in COVID-19, and the results were that in infected patients, the white blood cell and neutrophil count increased, while the lymphocyte and platelet counts decreased. In the other cases, coagulation abnormalities (prolonged PT and aPTT) and intravascular coagulopathy (DIC) were so correlated with low platelet count.

Comment 8:
Thank you for your very helpful comment. We revised the manuscript in Discussion paragraph 6.

D-Dimer in our study were measured using ELFA (enzyme linked fluorescent assay) method and cut off point 0.410 µg/ml. Several literatures showed different cut off point for D-Dimer. Poudel et al., with 182 subjects, showed D-Dimer levels of 1.5 µg/ml were an optimal cut off point to predict mortality. While Zhang, 2020, with 343 subjects, shows D-Dimer level 2 µg/ml were an optimal cut off point. Guan, 2020 in China, with 1099 subjects, showed that non-survivors had a significantly higher D-dimer (median: 2.12 µg/ml) than that of survivors (median: 0.61 µg/ml). This result could be due to differences in measurement methods as disclosed by Favaloro et al, who stated several things regarding the measurement and reporting quality of D-dimers, such as the measurement method, cut-off value, or D-dimer unit [D-dimer unit (DDU)] can lead to different research results.

Other factors in our study that can affect D-dimer level were our patients were older with median age 52, comorbidities such as cardiovascular disease and liver disease. Liver disease can affect D-Dimer elimination from blood. In this study D-dimer level was also measured on admission, very early in disease course. The half-life of D-dimer was approximately 8 hours therefore, serial measurement of D-dimer will shows more information

Competing Interests: No competing interests were disclosed.
The aim of this study is to evaluate and analyze risk factors of death, hematological and coagulation factors for COVID patients at RSUD Dr. Soetomo Surabaya. The parameters used in this manuscript were Hb, WBC, Neu#, lim#, NLR, platelet count, aPTT, PT, D-dimer, and CRP.

1. The statement "significantly different in the deceased group" might need to be rephrased to make it more clear.

2. In the discussions section under "survival analysis" it is stated that "leukopenia, leukocytosis, neutrophilia, high NLR, CRP and PT correlates with survival". This might confuse the readers. The writers might need to rephrase the statements to make it more in line with the abstract and with following statements.

3. The writers might need to detail the inclusion criteria used in the study. The writers stated that probable patients are included in the study, but the analysis is aimed more towards confirmed cases (the 217 subjects). In figure 1, it is indicated that 217 confirmed patients with complete data proceeded to statistical analysis.

4. The covid-19 degree of severity of the patients should be explained in more detail. This might help the reader to contextualize the term "non-ICU".

5. Kruskal Wallis method of analysis was not explained in the methods section.

6. The table 2 "comparison of the laboratory results in deceased and survived patients" may need some explanations. One example is that the writer used "above-normal result percentages".

7. Some grammatical errors might need to be addressed in the article.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** immunology, cancer thrombosis and platelet

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 28 Aug 2021

**Siprianus Ugroseno Yudho Bintoro**, Airlangga University, Surabaya, Indonesia

Dear Reviewer,

Thank you for reviewing and sending the feedback. We are going to revise it real soon.

Warm regards,

Research Team

**Competing Interests:** No competing interests were disclosed.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com